Glaxo Subpoenaed by DOJ Over Problems with Avandia
Amid ongoing accusations that the pharmaceutical giant GlaxoSmithKline knew their diabetes drug Avandia increased the risk of heart attacks and tried to suppress that information, the Department of Justice (DOJ) has subpoenaed the drug maker to gain access to clinical data and marketing information.
The DOJ subpoena has also been accompanied by Civil Investigation Demands issued by several state attorneys general offices. The inquiries were announced in GlaxoSmithKline’s third-quarter earnings statement (pdf), released on Thursday.
Glaxo’s statement indicates that the investigations are at an early stage, and that the company is cooperating. It also noted that new Avandia lawsuits continue to be filed claiming that the company failed to warn patients and doctors of heart risks associated with the drug.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Earlier this summer, Glaxo announced that it had reached Avandia settlements in about 10,000 cases, out of an estimated 13,000 that had been filed at the time.
Avandia (rosiglitazone) was first approved in the United States in 1998 to treat type 2 diabetes by helping control blood sugar levels. The drug has been used by millions of diabetics, but sales plummeted following the concerns about potential Avandia heart risks.
Last month, after a number of studies and internal debate, the FDA determined that only patients who have failed to control their diabetes through every other available medication should be given access to Avandia, and has ordered the company to develop a risk evaluation and mitigation strategy (REMS) to make sure the drug is adequately restricted. The decision came after an FDA advisory committee voted this summer to recommend that the drug stay on the market, but with strict warnings and restrictions.
The government investigations come after three years of contentious debate over the fate of the diabetes drug, which started with a 2007 study in the New England Medical Journal that suggested that Avandia increased the risk of heart attacks by 43%. A number of studies followed with some confirming the first study and others contradicting it.
Earlier this year, a Senate report on Avandia accused GlaxoSmithKline of suppressing the risks of Avandia, and indicated that many within the FDA have been calling for a recall of Avandia. The report claimed the company intimidated scientists and withheld data; accusations that the company denies.
Even the advisory committee hearing on Avandia has been mired in controversy. Some committee members were investigated for failing to disclose conflicts of interest, including one member who voted for no additional restrictions who was once paid to speak on Avandia panels. Some experts, including some FDA drug reviewers, say that the panel was loaded with members sympathetic to the company in order to avoid an Avandia recall.
ArnoldOctober 22, 2010 at 6:59 pm
It doesn't suprise me that the DOJ is involved; after all it is pretty plain to see that GSK provided fraudulent data. What does suprise me is the teeny tiny settlements people affected by this killer drug are getting. Of course a lawyer handling a class action case is going to get a pretty good payday from the settlement, unfortunently the individuals involved are getting far less than their case[Show More]It doesn't suprise me that the DOJ is involved; after all it is pretty plain to see that GSK provided fraudulent data. What does suprise me is the teeny tiny settlements people affected by this killer drug are getting. Of course a lawyer handling a class action case is going to get a pretty good payday from the settlement, unfortunently the individuals involved are getting far less than their cases are worth. Plain and simple, GSK is getting away with murder.
"*" indicates required fields
More Top Stories
A new report highlights how many women and families feel left out of Camp Lejeune settlement negotiations after suffering repeated miscarriages they say were caused by miscarriages on the North Carolina military base.
A Bard Infuse-A-Port lawsuit claims a piece of a failed port catheter broke off, causing a woman to suffer a pulmonary embolism which has resulted in fragments of the device remaining in her heart.
A Wegovy gastroparesis lawsuit blames the weight loss drug for a stomach paralysis problems which left a woman with permanent injuries.